Evaluation of the safety of nirmatrelvir-ritonavir in COVID
patients at high risk
Among patients treated with nirmatrelvir-ritonavir, 64 patients reported
the adverse effects. Out of these
patients, 19 (29.7%) encountered at least one form of adverse effects,
with gastrointestinal disorders (21.8%) being the prevailing side
effects (Table 3).